DOCSLIB.ORG

Effects of Pyrazinamide, Probenecid, and Benzbromarone on Renal Excretion of Oxypurinol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Pyrazinamide, Probenecid, and Benzbromarone on Renal Excretion of Oxypurinol Annals ofthe Rheumatic Diseases 1991; So: 631-633 631 Ann Rheum Dis: first published as 10.1136/ard.50.9.631 on 1 September 1991. Downloaded from Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol Tetsuya Yamamoto, Yuji Moriwaki, Sumio Takahashi, Michio Suda, Kazuya Higashino Abstract provided by Sankyo (Tokyo, Japan), Torii The effects of pyrazinamide, probenecid, and (Tokyo, Japan), and Banyu Pharmaceutical benzbromarone on renal excretion of oxy- (Tokyo, Japan) respectively. Other chemicals purinol were investigated. Pyrazinamide were obtained from Wako Pure Chemical decreased the mean (SEM) fractional clear- Industries (Osaka, Japan). ance of oxypurinol from 19-2 (2-1) to 8-8 (1-5). Probenecid increased the fractional clearance of oxypurinol from 14*1 (3.5) to 24-8 (4-1). ANALYSES OF PLASMA AND URINE SAMPLES Benzbromarone increased the fractional Plasma and urinary creatinine concentrations clearance of oxypurnol from 15-6 (2.3) to 33-8 were measured with a Wako creatinine test kit. (2.8). These results suggest that oxypurinol Oxypurinol in plasma and urine samples was may be secreted by 'an organic acid system' measured by high performance liquid chroma- and that oxypurinol is reabsorbed at a putative tography. The chromatography method postsecretory site of the renal tubules. described previously'3 was modified by combin- ing two reversed phase columns (Cl8 micro- sphere column) in series. 2,3-Pyrazinedicarbox- Oxypurinol is a major metabolite of allopurinol, amide, purified as reported previously,'4 was which is now widely used for the control of uric used as an internal standard for measuring acid production in patients with gout. Oxy- plasma oxypurinol. purinol is a strong inhibitor ofxanthine oxidase, its inhibitory potency being similar to that of allopurinol, and it has a longer half life (13-18 SUBJECrS AND PROTOCOL hours) than allopurinol (0-6-1-6 hour). l-5 Studies were made on 15 men, 26 to 39 years old Therefore, the effect of allopurinol on uric acid with no clinical history and who appeared production can be attributed almost entirely to healthy on physical examination, giving oxypurinol. In normal subjects and patients normal results in urine analyses, complete blood with gout allopurinol is mainly converted to counts, and routine blood chemical analyses. http://ard.bmj.com/ oxypurinol by xanthine oxidase, and oxypurinol They received only water for 12 hours before is then excreted unchanged by the kidney.2 The the study and were divided into three groups of concentration of serum oxypurinol is directly five. Allopurinol (300 mg) was given orally to all related to the renal clearance of oxypurinol,4 groups. After three and a half hours urine was which increases or decreases under various completely voided and then urine samples were conditions.4 6 For treatment of patients with collected twice at 30 minute intervals. Blood gout, therefore, it is important to understand samples were taken twice at the midpoints on September 27, 2021 by guest. Protected copyright. the renal excretion of oxypurinol. The renal excretion of oxypurinol seems to be similar to that of uric acid,4 7 but the renal transport Glomerular filtration mechanism(s) of oxypurinol has not yet been clearly elucidated. Probenecid and benzbro- marone are two uricosuric agents, which seem mainly to inhibit the renal reabsorption of uric acid at the postsecretory site8'0 (fig 1). Pyrazin- amide is an antituberculous agent and is well known to inhibit the renal secretion of uric acid8 (fig 1). These three agents have therefore been Third Department of used to study the renal transport of uric Internal Medicine, acid." 12 As the renal excretion of oxypurinol is Presecretory reabsorption Hyogo College of Medicine, similar to tht of uric acid,4 in this study we Nephron Mukogawa-cho 1-1, investigated the renal excretion of oxypurinol Tubular secretion Nishinomiya, Hyogo 663, using these drugs (pyrazinamide, probenecid, Japan and T Yamamoto benzbromarone). Y Moriwaki S Takahashi Postsecretory reabsorption M Suda Materials and methods K Higashino CHEMICALS 4 Correspondence to: Oxypurinol andallopurinol werekindly provided Figure I Renal transport ofuic acid in hwnans. Dr Yamamoto. Probenecid and benzbromarone each inhibit uric acid Accepted for publication by Tanabe (Osaka, Japan). Pyrazinamide, transport at (3). Pyrazinamide inhibits uric acid transport at 14 August 1990 benzbromarone, and probenecid were kindly (2). 632 Yamamoto, Mornvaki, Takahashi, Suda, Higashino 10a p= NS 2- p<0.05 100- p<0.005 between collections of urine samples with a Ann Rheum Dis: first published as 10.1136/ard.50.9.631 on 1 September 1991. Downloaded from heparinised syringe. The plasma was promptly separated. After the second urine sample had been taken the three groups received 2-0 g of probenecid, 300 mg of benzbromarone, or 3-0 g :5 of pyrazinamide respectively. One and a half -a ±~± E hours later urine was completely voided and aC Ei. x then urine samples were collected twice at 30 Lc 5- .O 50- x minute intervals. Blood samples were taken 0 twice at the midpoints between collections of E D x urine samples. This protocol was based on the 0 results of a preliminary study which showed I that the plasma concentration of oxypurinol was not significantly different four and six hours -1 after the intake of 300 mg of allopurinol. The 0 L 0 0 oxypurinol concentration of each sample was (1) (2) (1) (2) (1) (2) measured and the percentage ratio of oxypurinol Mean (SEM) 4-97 (0-79) 5-16 (0-75) 0-98 (0-24) 0-45 (0-13) 19-2 (2-1) 8-8 (1-5) clearance/creatinine clearance (fractional oxy- Figure 2 Effects ofpyrazinamide on plasma oxypurinol, unrnary ratio ofoxypurinol to purinol clearance, was calculated. The creatinine (UxlU,), andfractional oxypurinol clearance (F0x). (l)=controlperiod; Fo0) (2)=afterpyrazinamide treatment. means of variables in the control period and in the period after treatment with test drugs were calculated. 100- 10 p= NS 2- p < 0-005 pc 0-005 STATISTICAL ANALYSES Values are shown as means (SEM). Signifi- cances of differences in the means of variables in the control period and in the period after 5 treatment with test drugs were analysed by the E E two tailed, paired t test. 5 The variables cm ±-_± + examined were the plasma oxypurinol concen- x 50- tration, urinary ratio of oxypurinol to creatinine x and 0 (Uox/Ucr), F,x. * . ~~~~x ±( ,/ A Results EFFECT OF PYRAZINAMIDE ON OXYPURINOL 'iI Figure 2 shows mean values of various indices in the control period and after administration of http://ard.bmj.com/ (1) (2) (1) (2) (1) (2) pyrazinamide. After pyrazinamide treatment Mean (SEM) 4-96 (0-50) 4-72 (038) 0-72 (0-11) 1-17 (0-07) 14-1 (35) 24-8 (4-1) the plasma concentration of oxypurinol did not Figure 3 Effects ofprobenecid on plasma oxypurinol, urinary ratio ofoxypurinol to change, but Uox/Ucr and Fox decreased from creatinine (UO.XU,), andfractional oxypurinol clearance (F00). (1)=controlperiod; 0-98 (0-24) to 0-45 (0-13) (p<005) and from (2)=afterprobenecid treatment. 19-2 (2-1) to 8-8 (1-5) (p<0005) respectively. on September 27, 2021 by guest. Protected copyright. EFFECT OF PROBENECID ON OXYPURINOL Figure 3 shows mean values of various indices p<0-005 in the control period and after the probenecid treatment. Probenecid treatment did not affect 10- p= NS 100- pc 0-005 the plasma concentrations of oxypurinol, but it caused an increase in Uox/Ucr from 0-72 (0-11) to 117 (0 07) (p<0005) and an increase in Fox from 14-1 (3-5) to 24-8 (4-1) (p<0005) respec- tively. E :5 -a E E EFFECT OF BENZBROMARONE ON OXYPURINOL > 5- ls1- L 50- CL Figure 4 shows mean values of various indices x 0 in the control period and after benzbromarone E x 0 treatment. This drug did not affect the plasma concentration of oxypurinol but caused an increase in Uo,IUcr from 0-87 (0-14) to 1-67 D (0-26) (p<0005) and an increase in Fox from 15-6 (2-3) to 33-8 (2-8) (p<0-005) respectively. 0 (1) (2) (1) (2) (1) (2) Mean (SEM) 4-94 (0-33) 4-66 0-87 (0-14) 1-67 (0-26) 15-6 (2-3) 33-8 (2-8) (0-32) Discussion Figure 4 Effects ofbenzbromarone on plasma oxypurinol, urinary ratio ofoxypurinol to creatinine (U0,JlUcr), andfractional oxypurinol clearance (F..). (I)=control period; There are reports that oxypurinol, like uric (2)=after benzbromarone treatment. acid, is reabsorbed by the renal tubules in Renal excretion ofoxypurinol 633 benzbromarone because all previous studies had IGlomerular filtration been conducted using a single high dose Ann Rheum Dis: first published as 10.1136/ard.50.9.631 on 1 September 1991. Downloaded from schedule (allopurinol 300 mg, benzbromarone 60 mg).'6 '7 Their speculation led us to suspect that even a single dose of benzbromarone might increase Fox if it exerted a sufficiently strong uricosuric action. Therefore, we tested the effect of a single very high dose schedule (allopurinol 300 mg, benzbromarone 300 mg) and found that benzbromarone did in fact Presecretory reabsorption increase F.. (fig 4), indicating that the hypouri- Nephron caemic effect of combination therapy with Tubular secretion allopurinol and benzbromarone on plasma uric acid may be less than additive, as reported by Von Loffler et al'8 and that oxypurinol may be -Postsecretory reabsorption reabsorbed at least at a postsecretory site of the tubules (fig 5). Figure S Hypothetical renal transport ofoxypurinol in I Appelbaum S J, Mayersohn M, Dorr T R, Perrier D. humans. Allopurinol kinetics and bioavailability: intravenous, oral and rectal administration.
Load more

Recommended publications
  • 207988Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207988Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Office of Medication Error Prevention and Risk Management RISK EVALUATION AND MITIGATION STRATEGY (REMS) REVIEW Date: December 20, 2015 Reviewer(s): Jasminder Kumar, PharmD Division of Risk Management (DRISK) Acting Team Leader: Jamie Wilkins Parker, Pharm.D., DRISK Deputy Director: Reema Mehta, Pharm.D., M.P.H., DRISK Director: Cynthia LaCivita, Pharm.D. Subject: Review evaluates if a REMS is needed for Zurampic (lesinurad) Drug Name: Zurampic (lesinurad) Therapeutic Class: Uricosuric agent Dosage form and route: 200mg tablet for oral administration Application Type/Number: NDA 207988 Applicant/Sponsor: Ardea Biosciences Inc. OSE RCM #: 2015-52 *** This document contains proprietary and confidential information that should not be released to the public. *** 1 Reference ID: 3863300 CONTENTS 1 INTRODUCTION ................................................................................................................... 3 1.1 Product Background ......................................................................................................... 3 1.2 Disease Background ......................................................................................................... 3 1.3 Regulatory History ..........................................................................................................
    [Show full text]
  • Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia DINESH KHANNA,1 JOHN D
    Arthritis Care & Research Vol. 64, No. 10, October 2012, pp 1431–1446 DOI 10.1002/acr.21772 © 2012, American College of Rheumatology SPECIAL ARTICLE 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia DINESH KHANNA,1 JOHN D. FITZGERALD,2 PUJA P. KHANNA,1 SANGMEE BAE,2 MANJIT K. SINGH,3 TUHINA NEOGI,4 MICHAEL H. PILLINGER,5 JOAN MERILL,6 SUSAN LEE,7 SHRADDHA PRAKASH,2 MARIAN KALDAS,2 MANEESH GOGIA,2 FERNANDO PEREZ-RUIZ,8 WILL TAYLOR,9 FRE´ DE´ RIC LIOTE´ ,10 HYON CHOI,4 JASVINDER A. SINGH,11 NICOLA DALBETH,12 SANFORD KAPLAN,13 VANDANA NIYYAR,14 DANIELLE JONES,14 STEVEN A. YAROWS,15 BLAKE ROESSLER,1 GAIL KERR,16 CHARLES KING,17 GERALD LEVY,18 DANIEL E. FURST,2 N. LAWRENCE EDWARDS,19 BRIAN MANDELL,20 H. RALPH SCHUMACHER,21 MARK ROBBINS,22 2 7 NEIL WENGER, AND ROBERT TERKELTAUB Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determi- nation regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.
    [Show full text]
  • Colchicine and Probenecid | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Colchicine and Probenecid This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. What is this drug used for? It is used to prevent gouty arthritis. What do I need to tell my doctor BEFORE I take this drug? For all patients taking this drug: If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Blood problems or kidney stones. If you have any of these health problems: Kidney disease or liver disease. If you are pregnant or may be pregnant. Do not take this drug if you are pregnant. If you are taking a salicylate drug like aspirin. If you have liver or kidney problems and you take certain other drugs. Very bad and sometimes deadly side effects have happened in these people. There are many drugs that can do this. Ask your doctor or pharmacist if you are not sure. Children: If the patient is a child younger than 2 years of age. Do not give this drug to a child younger than 2 years of age. Colchicine and Probenecid 1/6 This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems.
    [Show full text]
  • Lesinurad Cuts Uric Acid in Refractory Gout
    20 ARTHRITIS AUGUST 2011 • RHEUMATOLOGY NEWS Lesinurad Cuts Uric Acid in Refractory Gout Ninety percent of patients who remained on fore the end of this year, said Barry D. a uric acid transporter molecule in the Quart, Pharm.D., president of Ardea kidney that takes uric acid out of urine treatment for 28 weeks met the study’s target level. Biosciences, the San Diego–based com- and places it back into the blood. pany that is developing the drug. The study led by Dr. Perez-Ruiz en- BY MITCHEL L. ZOLER mg/day of lesinurad also appeared safe, The phase III study will likely focus on rolled patients who met the 1977 gout di- with no adverse effects or other safety the 200-mg and 400-mg/day dosages, as agnosis criteria of the American FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY concerns seen during the limited treat- over time most patients appeared to re- Rheumatism Association (now the ment period reported, said Dr. Perez- spond to these lower dosages. American College of Rheumatology) LONDON – An investigational drug Ruiz, a rheumatologist at Hospital de “Almost no one needs 600 mg/day to and who had a serum uric acid level that boosts uric acid secretion led to sig- Cruces in Barakaldo, Spain. get a response,” Dr. Quart said in an in- greater than 6 mg/dL despite being on terview. a stable dose of 200-600 mg allopurinol Major Finding: After 4 weeks of treatment with a combination of 200-600 Although the current study used pa- for at least 6 weeks.
    [Show full text]
  • Gout Management in Swiss Primary Care – a Retrospective Observational Study
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2020 Gout management in Swiss primary care - a retrospective observational study Meier, Rahel ; di Gangi, Stefania ; Valeri, Fabio ; Rosemann, Thomas ; Zechmann, Stefan Abstract: BACKGROUND Gout is the most common form of inflammatory arthritis worldwide and its prevalence is rising. In Switzerland, there are no data available on the characteristics and treat- ment of gout patients. In this study, we aimed to describe numbers of patients affected by gout and hyperuricaemia and unveil approaches Swiss primary care physicians (PCPs) use for the management. METHODS This was a retrospective observational study using electronic medical routine nbsp;data pro- vided from 242 Swiss PCPs. Included were all their patients receiving urate-lowering therapy (ULT), with a diagnostic code for gout or who had a serum uric acid (SUA) measurement. According to their disease status, patients were classified into four subgroups (normal urate, hyperuricaemia, untreated gout, treated gout). For treatment analysis, patients with SUA measurements before and after ULT initiation were in- cluded. Comorbidities and risk factors for secondary causes relevant in the context of gout were collected. Outcomes were prevalence of gout and hyperuricaemia, characteristics of patients according to subgroup, number of SUA measurements, levels of SUA and patients who reached the treatment goal of a SUA level lt;360 micro;mol/l. RESULTS We assessed 15,808 patients and classified them into the subgroups. This yielded a prevalence of 1.0% for gout and 1.2% for hyperuricaemia. 2642 patients were diagnosed with gout of whom 2420 (91.6%) received a ULT.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Discontinuation of Urate-Lowering Drugs: a Systematic Review Protocol
    Discontinuation of urate-lowering drugs: a systematic review protocol Virginie Beslon, Perrine Moreau, Annabel Maruani, Hubert Maisonneuve, Bruno Giraudeau, Jean-Pascal Fournier ADMINISTRATIVE INFORMATION Registration PROSPERO registration number: Review team Virginie Beslon, Département de médecine générale, Université de Nantes, France ; [email protected] Perrine Moreau, Département de médecine générale, Université de Nantes, France ; [email protected] Annabel Maruani, Services de dermatologie, CHRU de Tours, Université François Rabelais, Tours, France ; [email protected] Hubert Maisonneuve, Unité des Internistes Généralistes et Pédiatres, Faculté de Médecine, Université de Genève, Suisse ; [email protected] Bruno Giraudeau, INSERM CIC 1415, CHRU de Tours, Université François-Rabelais, Tours, France ; [email protected] Jean-Pascal Fournier, Département de médecine générale, EA 4275-SPHERE, Université de Nantes, France ; [email protected] Contact details Jean-Pascal Fournier (guarantor) Département de médecine générale, Université de Nantes EA 4275-SPHERE, Biostatistique, Recherche Clinique et Mesures Subjectives en Santé, Université de Nantes 1 rue, Gaston Veil, 44000, Nantes, France [email protected] Contributions 1. Draft the protocol: VB, PM, AM, HM, BG, JPF 2. Study selection: VB, PM, JPF 3. Extract data from studies: VB, PM, JPF 4. Carry out the analysis: VB, PM, JPF 5. Interpret the analysis: VB, PM, AM, HM, BG, JPF 6. Draft the final review: VB, PM, JPF 7. Critical revision of the review for important intellectual content: VB, PM, AM, HM, BG, JPF Anticipated or actual start date December 30, 2015 Anticipated completion date October 30, 2016 Dissemination plans This paper will be submitted to a leading journal in this field.
    [Show full text]
  • Antihyperuricemics Review 10/25/2010
    Antihyperuricemics Review 10/25/2010 Copyright © 2009 – 2010 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 10101 Alliance Rd, Ste 201 Cincinnati, Ohio 45242 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. Antihyperuricemics Review FDA-Approved Indications1,2 Drug Manufacturer Indication(s) allopurinol generic - Management of patients with signs and symptoms (Zyloprim® )3 of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
    [Show full text]
  • Lesinurad Combined with Allopurinol
    ARTHRITIS & RHEUMATOLOGY Vol. 69, No. 1, January 2017, pp 203–212 DOI 10.1002/art.39840 VC 2016, American College of Rheumatology Lesinurad Combined With Allopurinol A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study) Kenneth G. Saag,1 David Fitz-Patrick,2 Jeff Kopicko,3 Maple Fung,3 Nihar Bhakta,3 Scott Adler,4 Chris Storgard,3 Scott Baumgartner,3 and Michael A. Becker5 Objective. Lesinurad is a selective uric acid re- serum UA level of <6.0 mg/dl at month 6. Key secondary absorption inhibitor used for the treatment of gout in com- end points were the mean gout flare rate requiring treat- bination with a xanthine oxidase inhibitor. The Combining ment (months 7–12) and the proportions of patients with Lesinurad with Allopurinol Standard of Care in Inade- complete resolution of ‡1 target tophus (month 12). Safety quate Responders (CLEAR 1) study, a 12-month, multi- assessments included adverse events and laboratory data. center, randomized, double-blind, placebo-controlled Results. The study patients (n 5 603) were predom- phase III trial, was conducted to investigate daily lesinurad inantlymaleandhadamean6 SD age of 51.9 6 11.3 (200 mg or 400 mg orally) added to allopurinol versus pla- years, a gout duration of 11.8 6 9.4 years, a baseline serum cebo plus allopurinol in patients with serum urate (UA) UA level of 6.94 6 1.27 mg/dl, and were receiving an allopu- levels above a target of <6.0 mg/dl.
    [Show full text]
  • Febuxostat: a Safe and Effective Therapy for Hyperuricemia and Gout
    DRUG EVALUATION Febuxostat: a safe and effective therapy for hyperuricemia and gout Natasha Jordan† & Febuxostat is a novel, nonpurine, selective xanthine oxidase inhibitor and is a potential Geraldine M McCarthy alternative to allopurinol for patients with hyperuricemia and gout. Unlike allopurinol, which †Author for correspondence undergoes renal elimination, febuxostat is metabolized via hepatic conjugation and Mater Misericordiae oxidation. Phase III studies have shown that febuxostat, at a once-daily dose of 80, 120 or University Hospital, Eccles St. Dublin 7, Ireland 240 mg (safety dose), is more effective than allopurinol (300 mg) in reducing and Tel.: + 35 316 405 514; maintaining serum urate concentrations lower than 6 mg/dl. Reductions in gout flares and [email protected] tophus areas with febuxostat treatment are similar to those occurring with allopurinol therapy. Patients with moderate renal impairment can achieve significant serum urate reductions, without dose adjustments. Therefore, febuxostat represents a viable treatment choice, with documented efficacy and safety in hyperuricemia and gout. Gout is a disease in which tissue deposition of agents) or by decreasing urate synthesis (xan- monosodium urate crystals occurs as a result of thine oxidase inhibitors). These therapeutic hyperuricemia, defined as a serum urate concen- options are not without their limitations. tration that exceeds the limit of solubility (∼6.8 mg/dl [400 µmol/l]). Clinical manifesta- Market overview tions include recurrent attacks of acute inflam- Allopurinol is a competitive inhibitor of xanthine matory arthritis, accumulation of urate crystals oxidase, preventing the oxidation of xanthine to in the form of tophaceous deposits and nephro- uric acid. Allopurinol and its active metabolite, pathy.
    [Show full text]
  • Vinblastine and Sulfinpyrazone Export by the Multidrug Resistance Protein MRP2 Is Associated with Glutathione Export
    British Journal of Cancer (2000) 83(3), 375–383 © 2000 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1262, available online at http://www.idealibrary.com on Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export R Evers1,4, M de Haas1, R Sparidans2, J Beijnen2, PR Wielinga3, J Lankelma3 and P Borst1 1Division of Molecular Biology and Center of Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Pharmacy, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands; 3Academic Hospital Vrije Universiteit, Department of Medical Oncology, Room BR232, PO Box 7057, 1007 MB Amsterdam, The Netherlands; 4Present address Georg-Speyer-Haus, Paul Ehrlich straße 42–44, 60596 Frankfurt am, Germany Summary The multidrug resistance proteins MRP1 and MRP2 are members of the same subfamily of ATP-binding cassette transporters. Besides organic molecules conjugated to negatively charged ligands, these proteins also transport cytotoxic drugs for which no negatively charged conjugates are known to exist. In polarized MDCKII cells, MRP1 routes to the lateral plasma membrane, and MRP2 to the apical plasma membrane. In these cells MRP1 transports daunorubicin, and MRP2 vinblastine; both transporters export reduced glutathione (GSH) into the medium. We demonstrate that glutathione transport in MDCKII-MRP1 cells is inhibited by the inhibitors of organic anion transporters sulfinpyrazone, indomethacin, probenecid and benzbromarone. In MDCKII-MRP2 cells, GSH export is stimulated by low concentrations of sulfinpyrazone or indomethacin, whereas export is inhibited down to control levels at high concentrations. We find that unmodified sulfinpyrazone is a substrate for MRP2, also at concentrations where GSH export is inhibited.
    [Show full text]
  • Highly Eribulin-Resistant KBV20C Oral Cancer Cells Can Be Sensitized By
    ANTICANCER RESEARCH 37 : 4139-4146 (2017) doi:10.21873/anticanres.11801 Highly Eribulin-resistant KBV20C Oral Cancer Cells Can Be Sensitized by Co-treatment with the Third-generation P-Glycoprotein Inhibitor, Elacridar, at a Low Dose YUJIN PARK*, JI-YEON SON*, BYUNG-MU LEE, HYUNG SIK KIM and SUNGPIL YOON School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea Abstract. Background/Aim: Eribulin mesylate, also called resistant cancer cells can be sensitized with cyclosporine A Halaven ® (HAL), was recently developed as a microtubule- or elacridar, specific P-gp inhibitors that exert their effects targeting drug and is used in the clinic for resistant or at a low dose. These findings provide important information metastatic cancer. Previously, we showed that P-glycoprotein regarding the sensitization of highly HAL-resistant cells with (P-gp)-overexpressing KBV20C oral cancer cells are highly selective P-gp inhibitors and indicate that elacridar may be resistant to HAL compared to sensitive KB cells. This used to treat such highly HAL-resistant cancer cells. qualitative study was designed to identify specific P-gp inhibitors that increase the sensitivity of highly resistant Anti-mitotic drugs, which target different binding sites on cancer cells to HAL. Materials and Methods: In order to tubulin, are widely used for treating different types of cancer identify functional P-gp inhibitors, HAL-treated KBV20C (1, 2). These compounds inhibit mitosis by targeting cells were co-treated with P-gp inhibitors, verapamil, microtubules and preventing their polymerization or elacridar, cyclosporine A, mitotane, piperine, fumagillin, depolymerization (3, 4). Eribulin, also called Halaven ® curcumin, indomethacin, probenecid, sulindac, tesmilifene, (HAL), was recently developed and used in the clinic to treat and C-4.
    [Show full text]